Metformin Use in Severe Renal Impairment

Introduction to Metformin Contraindications

A creatinine clearance of 25 mL/min falls below the safety threshold for metformin use, representing Stage 4 chronic kidney disease 1

The Kidney Disease Outcomes Quality Initiative (KDOQI) and other guideline societies recommend discontinuation of metformin when eGFR falls below 30 mL/min/1.73 m², due to the risk of lactic acidosis 2, 3, 1
For patients with eGFR ≥45 mL/min/1.73 m², metformin can be continued at standard doses, according to the American Journal of Kidney Diseases 2, 1
For patients with eGFR 30-44 mL/min/1.73 m², therapy should be reviewed, and dose reduction considered, with increased monitoring frequency, as recommended by the American Journal of Kidney Diseases 2, 1

DPP-4 inhibitors with appropriate renal dose adjustments are safer alternatives to metformin in severe renal impairment, with linagliptin requiring no dose adjustment, according to Praxis Medical Insights 1
Insulin therapy becomes the primary option for glycemic control in Stage 4-5 CKD, as recommended by Praxis Medical Insights 1
First-generation sulfonylureas should be avoided entirely, while second-generation sulfonylureas like glipizide are preferred over glyburide if sulfonylureas are needed, according to the American Journal of Kidney Diseases 3

The risk of metformin-associated lactic acidosis becomes unacceptable when eGFR falls below 30 mL/min/1.73 m², with a high mortality rate, according to Praxis Medical Insights 1
Serum creatinine alone should not be relied upon to make decisions about metformin use, and dose reduction should not be attempted at this level of renal function, as recommended by the American Journal of Kidney Diseases and Praxis Medical Insights 2, 1, 4